Cargando…

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain

Influenza is a contagious respiratory disease that causes severe illness and death, particularly in elderly populations. Two enhanced formulations of quadrivalent influenza vaccine (QIV) are available in Spain. Adjuvanted QIV (aQIV) is available for those aged 65+ and high-dose QIV (HD-QIV) for thos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Aragón, Jesús, Márquez-Peláez, Sergio, Gani, Ray, Alvarez, Piedad, Guerrero-Luduena, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879805/
https://www.ncbi.nlm.nih.gov/pubmed/35214635
http://dx.doi.org/10.3390/vaccines10020176
_version_ 1784658997123481600
author Ruiz-Aragón, Jesús
Márquez-Peláez, Sergio
Gani, Ray
Alvarez, Piedad
Guerrero-Luduena, Richard
author_facet Ruiz-Aragón, Jesús
Márquez-Peláez, Sergio
Gani, Ray
Alvarez, Piedad
Guerrero-Luduena, Richard
author_sort Ruiz-Aragón, Jesús
collection PubMed
description Influenza is a contagious respiratory disease that causes severe illness and death, particularly in elderly populations. Two enhanced formulations of quadrivalent influenza vaccine (QIV) are available in Spain. Adjuvanted QIV (aQIV) is available for those aged 65+ and high-dose QIV (HD-QIV) for those aged 60+. In this study, we used a health economic model to assess the costs and outcomes associated with using aQIV or HD-QIV in subjects aged 65+. Using aQIV instead of HD-QIV to vaccinate an estimated 5,126,343 elderly people results in reductions of 5405 symptomatic cases, 760 primary care visits, 171 emergency room visits, 442 hospitalizations, and 26 deaths in Spain each year. Life-years (LYs) and quality-adjusted LYs (QALYs) increases by 260 and 206, respectively, each year. Savings from a direct medical payer perspective are EUR 63.6 million, driven by the lower aQIV vaccine price and a minor advantage in effectiveness. From a societal perspective, savings increase to EUR 64.2 million. Results are supported by scenario and sensitivity analyses. When vaccine prices are assumed equal, aQIV remains dominant compared to HD-QIV. Potential savings are estimated at over EUR 61 million in vaccine costs alone. Therefore, aQIV provides a highly cost-effective alternative to HD-QIV for people aged 65+ in Spain.
format Online
Article
Text
id pubmed-8879805
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88798052022-02-26 Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain Ruiz-Aragón, Jesús Márquez-Peláez, Sergio Gani, Ray Alvarez, Piedad Guerrero-Luduena, Richard Vaccines (Basel) Article Influenza is a contagious respiratory disease that causes severe illness and death, particularly in elderly populations. Two enhanced formulations of quadrivalent influenza vaccine (QIV) are available in Spain. Adjuvanted QIV (aQIV) is available for those aged 65+ and high-dose QIV (HD-QIV) for those aged 60+. In this study, we used a health economic model to assess the costs and outcomes associated with using aQIV or HD-QIV in subjects aged 65+. Using aQIV instead of HD-QIV to vaccinate an estimated 5,126,343 elderly people results in reductions of 5405 symptomatic cases, 760 primary care visits, 171 emergency room visits, 442 hospitalizations, and 26 deaths in Spain each year. Life-years (LYs) and quality-adjusted LYs (QALYs) increases by 260 and 206, respectively, each year. Savings from a direct medical payer perspective are EUR 63.6 million, driven by the lower aQIV vaccine price and a minor advantage in effectiveness. From a societal perspective, savings increase to EUR 64.2 million. Results are supported by scenario and sensitivity analyses. When vaccine prices are assumed equal, aQIV remains dominant compared to HD-QIV. Potential savings are estimated at over EUR 61 million in vaccine costs alone. Therefore, aQIV provides a highly cost-effective alternative to HD-QIV for people aged 65+ in Spain. MDPI 2022-01-23 /pmc/articles/PMC8879805/ /pubmed/35214635 http://dx.doi.org/10.3390/vaccines10020176 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ruiz-Aragón, Jesús
Márquez-Peláez, Sergio
Gani, Ray
Alvarez, Piedad
Guerrero-Luduena, Richard
Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
title Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
title_full Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
title_fullStr Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
title_full_unstemmed Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
title_short Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
title_sort cost-effectiveness and burden of disease for adjuvanted quadrivalent influenza vaccines compared to high-dose quadrivalent influenza vaccines in elderly patients in spain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879805/
https://www.ncbi.nlm.nih.gov/pubmed/35214635
http://dx.doi.org/10.3390/vaccines10020176
work_keys_str_mv AT ruizaragonjesus costeffectivenessandburdenofdiseaseforadjuvantedquadrivalentinfluenzavaccinescomparedtohighdosequadrivalentinfluenzavaccinesinelderlypatientsinspain
AT marquezpelaezsergio costeffectivenessandburdenofdiseaseforadjuvantedquadrivalentinfluenzavaccinescomparedtohighdosequadrivalentinfluenzavaccinesinelderlypatientsinspain
AT ganiray costeffectivenessandburdenofdiseaseforadjuvantedquadrivalentinfluenzavaccinescomparedtohighdosequadrivalentinfluenzavaccinesinelderlypatientsinspain
AT alvarezpiedad costeffectivenessandburdenofdiseaseforadjuvantedquadrivalentinfluenzavaccinescomparedtohighdosequadrivalentinfluenzavaccinesinelderlypatientsinspain
AT guerreroluduenarichard costeffectivenessandburdenofdiseaseforadjuvantedquadrivalentinfluenzavaccinescomparedtohighdosequadrivalentinfluenzavaccinesinelderlypatientsinspain